Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
Parkinson's disease
levodopa
oxycodone
pain
parkinsonian central pain
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
revised:
03
05
2024
received:
19
03
2024
accepted:
16
05
2024
medline:
8
6
2024
pubmed:
8
6
2024
entrez:
8
6
2024
Statut:
aheadofprint
Résumé
Among the different types of pain related to Parkinson's disease (PD), parkinsonian central pain (PCP) is the most disabling. We investigated the analgesic efficacy of two therapeutic strategies (opioid with oxycodone- prolonged-release (PR) and higher dose of levodopa/benserazide) compared with placebo in patients with PCP. OXYDOPA was a randomized, double-blind, double-dummy, placebo-controlled, multicenter parallel-group trial run at 15 centers within the French NS-Park network. PD patients with PCP (≥30 on the Visual Analogue Scale [VAS]) were randomly assigned to receive oxycodone-PR (up to 40 mg/day), levodopa/benserazide (up to 200 mg/day) or matching placebo three times a day (tid) for 8 weeks at a stable dose, in add-on to their current dopaminergic therapy. The primary endpoint was the change in average pain intensity over the previous week rated on VAS from baseline to week-10 based on modified intention-to-treat analyses. Between May 2016 and August 2020, 66 patients were randomized to oxycodone-PR (n = 23), levodopa/benserazide (n = 20) or placebo (n = 23). The mean change in pain intensity was -17 ± 18.5 on oxycodone-PR, -8.3 ± 11.1 on levodopa/benserazide, and -14.3 ± 18.9 in the placebo groups. The absolute difference versus placebo was -1.54 (97.5% confidence interval [CI], -17.0 to 13.90; P = 0.8) on oxycodone-PR and +7.79 (97.5% CI, -4.99 to 20.58; P = 0.2) on levodopa/benserazide. Similar proportions of patients in each group experienced all-cause adverse events. Those leading to study discontinuation were most frequently observed with oxycodone-PR (39%) than levodopa/benserazide (5%) or placebo (15%). The present trial failed to demonstrate the superiority of oxycodone-PR or a higher dose of levodopa in patients with PCP, while oxycodone-PR was poorly tolerated. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Among the different types of pain related to Parkinson's disease (PD), parkinsonian central pain (PCP) is the most disabling.
OBJECTIVES
OBJECTIVE
We investigated the analgesic efficacy of two therapeutic strategies (opioid with oxycodone- prolonged-release (PR) and higher dose of levodopa/benserazide) compared with placebo in patients with PCP.
METHODS
METHODS
OXYDOPA was a randomized, double-blind, double-dummy, placebo-controlled, multicenter parallel-group trial run at 15 centers within the French NS-Park network. PD patients with PCP (≥30 on the Visual Analogue Scale [VAS]) were randomly assigned to receive oxycodone-PR (up to 40 mg/day), levodopa/benserazide (up to 200 mg/day) or matching placebo three times a day (tid) for 8 weeks at a stable dose, in add-on to their current dopaminergic therapy. The primary endpoint was the change in average pain intensity over the previous week rated on VAS from baseline to week-10 based on modified intention-to-treat analyses.
RESULTS
RESULTS
Between May 2016 and August 2020, 66 patients were randomized to oxycodone-PR (n = 23), levodopa/benserazide (n = 20) or placebo (n = 23). The mean change in pain intensity was -17 ± 18.5 on oxycodone-PR, -8.3 ± 11.1 on levodopa/benserazide, and -14.3 ± 18.9 in the placebo groups. The absolute difference versus placebo was -1.54 (97.5% confidence interval [CI], -17.0 to 13.90; P = 0.8) on oxycodone-PR and +7.79 (97.5% CI, -4.99 to 20.58; P = 0.2) on levodopa/benserazide. Similar proportions of patients in each group experienced all-cause adverse events. Those leading to study discontinuation were most frequently observed with oxycodone-PR (39%) than levodopa/benserazide (5%) or placebo (15%).
CONCLUSIONS
CONCLUSIONS
The present trial failed to demonstrate the superiority of oxycodone-PR or a higher dose of levodopa in patients with PCP, while oxycodone-PR was poorly tolerated. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The French Ministry of Health
ID : PHRCN-14-0044
Informations de copyright
© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Broen MP, Braaksma MM, Patijn J, et al. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord 2012;27:480–484.
Beiske AG, Loge JH, Rønningen A, et al. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009;141:173–177.
Brefel‐Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain 2009;141:14–18.
Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross‐sectional survey of its prevalence, specifics, and therapy. J Neurol 2017;264:758–769.
Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross‐sectional study. Parkinsonism Relat Disord 2004;10:129–136.
Marques A, Attal N, Bouhassira D, et al. How to diagnose parkinsonian central pain? Parkinsonism Relat Disord 2019;64:50–53.
Mylius V, Perez Lloret S, Cury R, et al. The Parkinson disease pain classification system: results from an international mechanism‐based classification approach. Pain 2021;162:1201–1210.
Buhmann C, Kassubek J, Jost WH. Management of Pain in Parkinson's disease. J Parkinsons Dis 2020;10:S37–S48.
Edinoff A, Sathivadivel N, McBride T, et al. Chronic pain treatment strategies in Parkinson's disease. Neurol Int 2020;12:61–76.
Gottlieb S, Woodcock J. Marshaling FDA benefit‐risk expertise to address the current opioid abuse epidemic. JAMA 2017;318:421–422.
Bouhassira D, Attal N. Translational neuropathic pain research: a clinical perspective. Neuroscience 2016;338:27–35.
Marques A, Brefel‐Courbon C. Chronic pain in Parkinson's disease: clinical and pathophysiological aspects. Rev Neurol 2021;177:394–399.
Ghosh P, Imbriani P, Caputi N, et al. A dual Centre study of pain in Parkinson's disease and its relationship with other non‐motor symptoms. J Parkinsons Dis 2020;10:1817–1825.
Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3–38.
Brefel‐Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005;20:1557–1563.
Brefel‐Courbon C, Ory‐Magne F, Thalamas C, et al. Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. Parkinsonism Relat. Disord 2013;19:548–552.
Gerdelat‐Mas A, Simonetta‐Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140–1142.
Schestatsky P, Kumru H, Valls‐Solé J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 2007;69:2162–2169.
Borsook D, Upadhyay J, Chudler EH, et al. A key role of the basal ganglia in pain and analgesia—insights gained through human functional imaging. Mol Pain 2010;6:27.
Trenkwalder C, Chaudhuri KR, Martinez‐Martin P, et al. Prolonged‐release oxycodone‐naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double‐blind, randomised, placebo‐controlled trial. Lancet Neurol 2015;14:1161–1170.
Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson's disease. Mov Disord 2009;24:1233–1237.
Genolini C, Lacombe A, Écochard R, et al. CopyMean: a new method to predict monotone missing values in longitudinal studies. Comput Methods Programs Biomed 2016;132:29–44.
Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–2653.
Edwards RR, Dworkin RH, Turk DC, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 2016;157:1851–1871.
Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146:238–244.
Witek N, Stebbins GT, Goetz CG. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord 2018;33:1204–1212.
Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: what we have learned and where we are going. Mov Disord 2018;33:1213–1227.
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008;65:220–231.
Blanchet PJ, Brefel‐Courbon C. Chronic pain and pain processing in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2018;2018(87):200–206.
Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 2015;156:2616–2626.
Thompson T, Gallop K, Correll CU, et al. Pain perception in Parkinson's disease: a systematic review and meta‐analysis of experimental studies. Ageing Res Rev 2017;35:74–86.
Rascol O, Zesiewicz T, Chaudhuri KR, et al. A randomized controlled exploratory pilot study to evaluate the effect of Rotigotine transdermal patch on Parkinson's disease‐associated chronic pain. J Clin Pharmacol 2016;56:852–861.
Grigoriou S, Martínez‐Martín P, Chaudhuri KR, et al. Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain Behav 2021;11:e2336.
Dellapina E, Gerdelat‐Mas A, Ory‐Magne F, et al. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2011;26:153–157.
Kim Y. Missing data handling in chronic pain trials. J Biopharm Stat 2011;21:311–325.
Huissoud M, Boussac M, Joineau K, et al. The effectiveness and safety of non‐pharmacological intervention for pain management in Parkinson's disease: a systematic review. Rev Neurol 2023. https://doi.org/10.1016/j.neurol.2023.04.010